Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.
Institutional & Insider Ownership
8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 13.3% of Cardio Diagnostics shares are held by company insiders. Comparatively, 0.1% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Cardio Diagnostics and Allarity Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardio Diagnostics | -39,674.18% | -67.51% | -62.27% |
| Allarity Therapeutics | N/A | -112.05% | -64.89% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardio Diagnostics | $15,782.00 | 209.42 | -$8.38 million | ($3.74) | -0.48 |
| Allarity Therapeutics | N/A | N/A | -$24.51 million | ($0.59) | -2.00 |
Cardio Diagnostics has higher revenue and earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Cardio Diagnostics has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Cardio Diagnostics and Allarity Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| Allarity Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Allarity Therapeutics has a consensus price target of $9.50, indicating a potential upside of 705.08%. Given Allarity Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Cardio Diagnostics.
Summary
Cardio Diagnostics beats Allarity Therapeutics on 7 of the 13 factors compared between the two stocks.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
About Allarity Therapeutics
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
